Osteosarcoma is the most common primary tumor of the bones affecting mainly young
adults. Despite the advances in the field of systemic anticancer therapy, the prognosis of …

Bone cancer is a critical health problem on a global scale, and the associated huge clinical
and economic burdens are still rising. Although many clinical approaches are currently used …

Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated
with a large biological spectrum ranging from latent benign to highly recurrent and …

Introduction: The EUROpean Bone Over 40 Sarcoma Study (EURO-BOSS) was the first
prospective international study for patients 41-65 years old with high-grade bone sarcoma …

Systemic inflammation responses have been associated with cancer development and
progression. C-reactive protein (CRP), Glasgow prognostic score (GPS), neutrophil …

Objective Health‐related quality of life (HRQoL), psychosocial distress, and unmet health
needs are important patient‐reported outcomes (PROs) for patients with sarcoma treated …

Objective Osteosarcoma often requires multidisciplinary treatment including surgery,
chemotherapy and radiotherapy. However, tumor behavior can vary widely among patients …

Background Even though immunotherapy has been an effective treatment for solid tumors,
its efficacy in osteosarcoma remains sub‐optimal. It is therefore imperative to understand the …

Resistin is an adipokine that is associated with obesity, inflammation, and various cancers.
Chondrosarcomas are primary malignant bone tumors that have a poor prognosis. VEGF-A …

Osteosarcoma (OS) is a common malignant bone cancer. The relatively high density of a
person's bone structure means low permeability for drugs, and so finding drugs that can be …